Numbers

The Numbers

Lyka Labs is a ₹214 Cr micro-cap Indian pharma formulator with a 20-year record of sub-scale operating performance, one extreme outlier year (FY22), and a post-FY22 re-rate that the business has not yet earned on cash-flow grounds. Reported FY25 looks like a turnaround (revenue ₹138 Cr, PAT ₹8 Cr, ROCE 10%, debt down from ₹163 Cr to ₹39 Cr) — but free cash flow has been negative for two consecutive years, working-capital drag has consumed every rupee of profit, and Q2 FY26 already printed an operating loss. The market cap today (₹214 Cr) implies a return to FY22-style profitability; the cash statements imply it has not returned.

Snapshot

Price (₹)

59.83

Market Cap (₹ Cr)

214

Revenue FY25 (₹ Cr)

138

PAT FY25 (₹ Cr)

FCF FY25 (₹ Cr)

-10

Book Value / Share (₹)

28.3

P/B

2.06

1-yr Return

20%

Priced at 2.06× book for a business whose 10-year cumulative FCF is negative and whose 10-year average ROCE is roughly 4%. The burden of proof is on the bull case.

Quality Scorecard

No third-party composite quality score is available for this micro-cap. The table below reconstructs the equivalent from first principles using the reported financials.

No Results

The Altman Z of 3.87 flatters this business. It relies heavily on the market-cap-to-liabilities ratio. Strip that out and the "profitability" and "productivity" components score in the distress zone.

Revenue & Earnings Power — 11-Year View

The one-year spike in FY22 (52% OPM, ₹38 Cr PAT) is almost certainly a related-party mix event — a surge in contract-manufacturing sales to promoter Ipca at unusually high margins. Every subsequent year has reverted to mid-teens OPM with thin or negative net profit once interest and tax normalize. The FY25 print of 13% OPM and ₹8 Cr PAT is a return to the pre-FY22 mean, dressed up by lower interest expense.

Quarterly Trajectory — What Is Actually Happening Now

**Q2 FY26 (Sep 2025) printed an operating loss of ₹2.5 Cr at 13% higher revenue than Q1.** This is the opposite of operating leverage and it breaks the turnaround narrative. Q3 FY26 (Dec 2025) recovered modestly (5.4% OPM) but remains below the mid-teens reported through FY24-FY25. The market is now marking this.

Cash Generation — Are the Earnings Real?

What this chart says. The FY22 year was real in cash terms (OCF of ₹79 Cr against ₹38 Cr PAT — a 2.1× conversion). FY23's negative PAT had positive OCF because a working-capital release was unwinding the FY22 buildup. But in FY24 and FY25 — the "recovery" years — OCF has collapsed to ₹2 Cr each year while capex has stepped up to finance the new Lyophilization Phase-I line, producing negative FCF of ₹7 Cr and ₹10 Cr. Reported profitability is not converting to cash.

Capital Allocation

Two facts on this chart. First, Lyka has paid no dividend in the last decade and bought back no shares. Second, the "debt reduced from ₹163 Cr to ₹39 Cr" story — which is the single most-repeated bull point — happened because promoter Ipca injected ₹34 Cr of fresh equity in FY25 (and ₹20 Cr earlier), not because the business generated cash. A genuine deleveraging would show a mirror-image positive FCF column here. It does not.

Balance Sheet Health

The balance sheet is the bull case. Net debt / EBITDA is now roughly 1.5× (₹39 Cr debt on ~₹25 Cr EBITDA), interest cost has collapsed from ₹26 Cr in FY21 to ₹2 Cr in FY25, and equity reserves are positive (₹68 Cr) for the first time in six years. **But this is solvency, not quality.** A clean balance sheet at 2× book is not by itself a reason to own a sub-scale formulator whose P&L went operating-loss two quarters ago.

Working-Capital Cyclicality — The Single Most Important Trend Line

Why this chart matters more than the P&L. The cash conversion cycle moved from minus 63 days (customers paid before Lyka paid suppliers) in FY21 to plus 97 days in FY25 — a 160-day swing. For a ₹138 Cr revenue business, every additional 10 days of CCC is roughly ₹4 Cr of working-capital drag. The four-year move cost the company ~₹65 Cr of cash that would otherwise have been FCF. This is not a pharma industry trend; Marksans, Caplin, and Windlas all have stable or improving CCCs. It is Lyka-specific, and it is the reason FY24 and FY25 printed negative FCF despite reporting operating profit.

Valuation — 20-Year Price History

What the 20-year chart is actually telling you. Lyka has had three distinct price regimes: (a) 2005-2014, where the stock traded ₹9-₹90 on a crumbling balance sheet and EPS that was negative in most years; (b) 2015-2020, a grinding slide from ₹128 to ₹20 as losses compounded and equity went negative; and (c) 2021-2024, a 10× rerate on the FY22 profit spike plus Ipca's 58% stake announcement. The 2026 print (₹60) has already retraced 65% from the mid-2025 peak of ₹129, bringing P/B to 2.06× — a level that historically (2015, 2019) has been followed by further de-rating when the operating results failed to justify it.

Peer Comparison

No Results

Lyka's 1.6× P/S is the second-lowest in the peer set — but on a revenue base of ₹138 Cr with negative FCF and 9.9% ROCE. Every peer with a meaningfully higher multiple has the ROCE to support it: Caplin at 28%, Marksans at 23%, Windlas at 17%. The discount isn't a bargain; it is the market correctly pricing sub-scale operations.

Fair Value & Scenarios

No Results

The bull case requires four consecutive quarters of positive FCF, debtor days compressing to 60, and a second anchor customer becoming a multi-year contract — none of which has started. The base case at ₹62 sits within 5% of today's price, suggesting the market is pricing in roughly the middle of the range, heavily weighted toward the muted scenario. For that to become mispricing, the working-capital story has to turn.

What I'd Watch

The three datapoints that will break the thesis, in rank order:

Q3 FY26 OCF-to-PAT conversion. If it prints below 0.5× again, the FY25 "turnaround" is mechanically over. A value above 1× alongside a flat-to-lower debtor-days number is the first genuine bullish signal in a decade.
Debtor days at Mar 2026. Currently 114. A move above 130 means working capital is the new bottleneck and the balance-sheet bull case erodes. A move to 80 or below would be the single most valuable positive signal.
Related-party disclosure in FY26 AR. If Ipca's revenue share crosses 25%, re-valuation should happen against Ipca's own multiples (a captive), not Lyka's peer group (a contract manufacturer).